ENSURE Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva) and Erlotinib After Disease Progression in Chinese Population Enrolled in the ENSURE Trial

Trial Profile

ENSURE Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva) and Erlotinib After Disease Progression in Chinese Population Enrolled in the ENSURE Trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2016

At a glance

  • Drugs Erlotinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 09 Mar 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 08 Dec 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 08 Dec 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top